Newstral
Robyn Karnauskas
- Pfizer, big drugmakers expected to hike prices on at least 500 drugs in JanuaryNew York Post
- Pfizer’s $14 billion COVID sales warning sparks investor reliefSydney Morning Herald
- IGilead stock is not out of room to run just yet: Truistinvezz.com
- BStreet Shrugs Off FDA's Call for Probe of Alzheimer's Drug Approval3 min readbarrons.com
- BIovance Stock Falls Almost 40% on Double Dose of Bad Newsbarrons.com
- BDon't Lose Sight of Biogen's Depression Drug Amid Focus on Alzheimer's Diseasebarrons.com
- BRegeneron Pharmaceuticals Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
- BGilead Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
- BThe U.S. Is Bailing Out Companies. Regeneron Doesn’t Need the Help.barrons.com
- BBuy Regeneron Stock, but Not Because of Its Covid-19 Antibody Cocktail, Analyst Saysbarrons.com
- BGilead Is Testing an Inhaled Version of Its Covid-19 Drugbarrons.com
- BGilead Will Make a Profit on Remdesivir This Year, Says Analystbarrons.com
- BGilead Finally Set a Price for Remdesivir. Analysts Disagree on What It Means.barrons.com
- BGilead Sciences Stock Is Moving Back Into Favorbarrons.com
- BGilead Could Sell $1.1 Billion of Remdesivir This Year, Analyst Writesbarrons.com
- BGilead Stock Drops on Wave of Downgradesbarrons.com
- MCOVID-19 treatment yields disappointing data in trial and shows it’s not easy to develop drugsmarketwatch.com
- BGilead’s Coronavirus Drug Saga Leaves Analysts Wanting More Databarrons.com
- Stocks are soaring on a potential coronavirus treatment. But it's not a silver bulletCNN
- BRegeneron Could Start a Covid-19 Treatment Test This Summerbarrons.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.